January 24, 2023 -- Harvard University researchers and collaborators conducted a modeling study that showed tuberculosis (TB) vaccination could be cost-effective in 73 of 105 (70%) low- and middle-income countries. The results, published on January 24 in PLOS Medicine, also predicted $474 billion in vaccine-related benefits by 2050.
